FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Franz Vollenweider

Research Profile

Chemicals & Drugs

Disorders

Procedures

Concepts & Ideas

Co-author Network

Publications

TOP 3
Dominique H Holstein; Franz Vollenweider; Nadine Belser; Philipp Csomor; Mark A Geyer; Dominique Eich
Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD).
Boris B Quednow; Katharina M Rentsch; Pius August Schubiger; Valerie Treyer; Alfred Buck; Cyrill Burger; Nadja Dörig; Felix Hasler; Gerrit Westera; Matthias T Wyss; Franz Vollenweider
Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.
Rainer Kraehenmann; Erich Seifritz; Franz Vollenweider; Michael Kometer
Crowding deficits in the visual periphery of schizophrenia patients.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Franz Vollenweider (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Dominique H Holstein; Franz Vollenweider; Nadine Belser; Philipp Csomor; Mark A Geyer; Dominique Eich
Sensory and sensorimotor gating in adult attention-deficit/hyperactivity disorder (ADHD).
Psychiatry research 2013;205(1-2):117-26.
2012: Boris B Quednow; Katharina M Rentsch; Pius August Schubiger; Valerie Treyer; Alfred Buck; Cyrill Burger; Nadja Dörig; Felix Hasler; Gerrit Westera; Matthias T Wyss; Franz Vollenweider
Assessment of serotonin release capacity in the human brain using dexfenfluramine challenge and [18F]altanserin positron emission tomography.
NeuroImage 2012;59(4):3922-32.
2012: Rainer Kraehenmann; Erich Seifritz; Franz Vollenweider; Michael Kometer
Crowding deficits in the visual periphery of schizophrenia patients.
PloS one 2012;7(9):e45884.
2012: Erich Studerus; Alex Gamma; Michael Kometer; Franz Vollenweider
Prediction of psilocybin response in healthy volunteers.
PloS one 2012;7(2):e30800.
2011: Michael Kometer; B Rael Cahn; David Andel; Olivia L Carter; Franz Vollenweider
The 5-HT2A/1A agonist psilocybin disrupts modal object completion associated with visual hallucinations.
Biological psychiatry 2011;69(5):399-406.
2010: Dominique H Holstein; Franz Vollenweider; Lutz Jäncke; Christian Schopper; Philipp Csomor
P50 suppression, prepulse inhibition, and startle reactivity in the same patient cohort suffering from posttraumatic stress disorder.
Journal of affective disorders 2010;126(1-2):188-97.
2010: Franz Vollenweider; Michael Kometer
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders.
Nature reviews. Neuroscience 2010;11(9):642-51.
2010: C M Hysek; Franz Vollenweider; Matthias E Liechti
Effects of a beta-blocker on the cardiovascular response to MDMA (Ecstasy).
Emergency medicine journal : EMJ 2010;27(8):586-9.
2010: Patrik Roser; Franz Vollenweider; Wolfram Kawohl
Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists.
The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry 2010;11(2 Pt 2):208-19.
2010: Erich Studerus; Alex Gamma; Franz Vollenweider
Psychometric evaluation of the altered states of consciousness rating scale (OAV).
PloS one 2010;5(8):e12412.
2010: Caroline C Hilti; Tarik Delko; Ariane T Orosz; Kathrin Thomann; Stephan Ludewig; Mark A Geyer; Franz Vollenweider; Joram Feldon; Katja Cattapan-Ludewig
Sustained attention and planning deficits but intact attentional set-shifting in neuroleptic-naïve first-episode schizophrenia patients.
Neuropsychobiology 2010;61(2):79-86.
2009: Felix Hasler; E Studerus; K Lindner; Stephan Ludewig; Franz Vollenweider
Investigation of serotonin-1A receptor function in the human psychopharmacology of MDMA.
Journal of psychopharmacology (Oxford, England) 2009;23(8):923-35.
2009: Boris B Quednow; Anne Schmechtig; Ulrich Ettinger; Nadine Petrovsky; David A Collier; Franz Vollenweider; Michael Wagner; Veena Kumari
Sensorimotor gating depends on polymorphisms of the serotonin-2A receptor and catechol-O-methyltransferase, but not on neuregulin-1 Arg38Gln genotype: a replication study.
Biological psychiatry 2009;66(6):614-20.
2009: Felix Hasler; O F Kuznetsova; R N Krasikova; T Cservenyak; Boris B Quednow; Franz Vollenweider; Simon M Ametamey; Gerrit Westera
GMP-compliant radiosynthesis of [18F]altanserin and human plasma metabolite studies.
Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine 2009;67(4):598-601.
2009: Philipp Csomor; Benjamin K Yee; Joram Feldon; Anastasia Theodoridou; Erich Studerus; Franz Vollenweider
Impaired prepulse inhibition and prepulse-elicited reactivity but intact reflex circuit excitability in unmedicated schizophrenia patients: a comparison with healthy subjects and medicated schizophrenia patients.
Schizophrenia bulletin 2009;35(1):244-55.
2008: Mark A Geyer; Franz Vollenweider
Serotonin research: contributions to understanding psychoses.
Trends in pharmacological sciences 2008;29(9):445-53.
2008: Philipp Csomor; Benjamin K Yee; Franz Vollenweider; Joram Feldon; Tiana Nicolet; Boris B Quednow
On the influence of baseline startle reactivity on the indexation of prepulse inhibition.
Behavioral neuroscience 2008;122(4):885-900.
2008: Boris B Quednow; Philipp Csomor; Joelle Chmiel; Thilo Beck; Franz Vollenweider
Sensorimotor gating and attentional set-shifting are improved by the mu-opioid receptor agonist morphine in healthy human volunteers.
The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP) 2008;11(5):655-69.
2008: Jirí Wackermann; Marc Wittmann; Felix Hasler; Franz Vollenweider
Effects of varied doses of psilocybin on time interval reproduction in human subjects.
Neuroscience letters 2008;435(1):51-5.
2008: Katja Cattapan-Ludewig; Stephan Ludewig; Nadine Messerli; Franz Vollenweider; Antonia Seitz; Joram Feldon; Martin P Paulus
Decision-making dysregulation in first-episode schizophrenia.
The Journal of nervous and mental disease 2008;196(2):157-60.
2008: Philipp Csomor; Renée R Stadler; Joram Feldon; Benjamin K Yee; Mark A Geyer; Franz Vollenweider
Haloperidol differentially modulates prepulse inhibition and p50 suppression in healthy humans stratified for low and high gating levels.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2008;33(3):497-512.
2007: Olivia L Carter; Felix Hasler; John D Pettigrew; Guy Wallis; Guang B Liu; Franz Vollenweider
Psilocybin links binocular rivalry switch rate to attention and subjective arousal levels in humans.
Psychopharmacology 2007;195(3):415-24.
2007: Franz Vollenweider; Philipp Csomor; Bernhard Knappe; Mark A Geyer; Boris B Quednow
The effects of the preferential 5-HT2A agonist psilocybin on prepulse inhibition of startle in healthy human volunteers depend on interstimulus interval.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2007;32(9):1876-87.
2007: Marc Wittmann; Olivia L Carter; Felix Hasler; B Rael Cahn; Ulrike Grimberg; Philipp Spring; Daniel Hell; Hans Flohr; Franz Vollenweider
Effects of psilocybin on time perception and temporal control of behaviour in humans.
Journal of psychopharmacology (Oxford, England) 2007;21(1):50-64.
2006: Philipp Csomor; Benjamin K Yee; Boris B Quednow; Renée R Stadler; Joram Feldon; Franz Vollenweider
The monotonic dependency of prepulse inhibition of the acoustic startle reflex on the intensity of the startle-eliciting stimulus.
Behavioural brain research 2006;174(1):143-50.
2006: Franz Vollenweider; Martine Barro; Philipp Csomor; Jorame Feldon
Clozapine enhances prepulse inhibition in healthy humans with low but not with high prepulse inhibition levels.
Biological psychiatry 2006;60(6):597-603.
2005: Olivia L Carter; David C Burr; John D Pettigrew; Guy Wallis; Felix Hasler; Franz Vollenweider
Using psilocybin to investigate the relationship between attention, working memory, and the serotonin 1A and 2A receptors.
Journal of cognitive neuroscience 2005;17(10):1497-508.
2005: Alex Gamma; Daniel Brandeis; Ruven Brandeis; Franz Vollenweider
The P3 in 'ecstasy' polydrug users during response inhibition and execution.
Journal of psychopharmacology (Oxford, England) 2005;19(5):504-12.
2005: Philipp Csomor; Franz Vollenweider; Joram Feldon; Benjamin K Yee
On the feasibility to detect and to quantify prepulse-elicited reaction in prepulse inhibition of the acoustic startle reflex in humans.
Behavioural brain research 2005;162(2):256-63.
2005: Franz Vollenweider; Matthias E Liechti; Martin P Paulus
MDMA affects both error-rate dependent and independent aspects of decision-making in a two-choice prediction task.
Journal of psychopharmacology (Oxford, England) 2005;19(4):366-74.
2005: Olivia L Carter; John D Pettigrew; Felix Hasler; Guy Wallis; Guang B Liu; Daniel Hell; Franz Vollenweider
Modulating the rate and rhythmicity of perceptual rivalry alternations with the mixed 5-HT2A and 5-HT1A agonist psilocybin.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2005;30(6):1154-62.
2005: Katja Cattapan-Ludewig; Caroline C Hilti; Stephan Ludewig; Franz Vollenweider; Joram Feldon
Rapid visual information processing in schizophrenic patients: the impact of cognitive load and duration of stimulus presentation. A pilot study.
Neuropsychobiology 2005;52(3):130-4.
2005: Stephan Ludewig; Mark A Geyer; Marcel Ramseier; Franz Vollenweider; Evelyne Rechsteiner; Katja Cattapan-Ludewig
Information-processing deficits and cognitive dysfunction in panic disorder.
Journal of psychiatry & neuroscience : JPN 2005;30(1):37-43.
2004: Olivia L Carter; John D Pettigrew; David C Burr; David Alais; Felix Hasler; Franz Vollenweider
Psilocybin impairs high-level but not low-level motion perception.
Neuroreport 2004;15(12):1947-51.
2004: Alex Gamma; Dietrich Lehmann; Edi Frei; Kazuki Iwata; Roberto D Pascual-Marqui; Franz Vollenweider
Comparison of simultaneously recorded [H2(15)O]-PET and LORETA during cognitive and pharmacological activation.
Human brain mapping 2004;22(2):83-96.
2004: Felix Hasler; Ulrike Grimberg; Marco A Benz; Theo Huber; Franz Vollenweider
Acute psychological and physiological effects of psilocybin in healthy humans: a double-blind, placebo-controlled dose-effect study.
Psychopharmacology 2004;172(2):145-56.
2003: Stephan Ludewig; Martin P Paulus; Katja Ludewig; Franz Vollenweider
Decision-making strategies by panic disorder subjects are more sensitive to errors.
Journal of affective disorders 2003;76(1-3):183-9.
2003: Katja Ludewig; Martin P Paulus; Franz Vollenweider
Behavioural dysregulation of decision-making in deficit but not nondeficit schizophrenia patients.
Psychiatry research 2003;119(3):293-306.
2003: Katja Ludewig; Mark A Geyer; Franz Vollenweider
Deficits in prepulse inhibition and habituation in never-medicated, first-episode schizophrenia.
Biological psychiatry 2003;54(2):121-8.
2003: Katja Ludewig; Stephan Ludewig; Antonia Seitz; Martina Obrist; Mark A Geyer; Franz Vollenweider
The acoustic startle reflex and its modulation: effects of age and gender in humans.
Biological psychology 2003;63(3):311-23.
2003: Franz Vollenweider; MF Vollenweider-Scherpenhuyzen
[Hallucinogens, amphetamines and entactogens].
Therapeutische Umschau. Revue thérapeutique 2003;60(6):323-8.
2003: Daniel Umbricht; Franz Vollenweider; Liselotte Schmid; Claudia Grübel; Anja Skrabo; Theo Huber; Rupert Koller
Effects of the 5-HT2A agonist psilocybin on mismatch negativity generation and AX-continuous performance task: implications for the neuropharmacology of cognitive deficits in schizophrenia.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2003;28(1):170-81.
2002: Lorenz Leumann; Joram Feldon; Franz Vollenweider; Katja Ludewig
Effects of typical and atypical antipsychotics on prepulse inhibition and latent inhibition in chronic schizophrenia.
Biological psychiatry 2002;52(7):729-39.
2002: Felix Hasler; Daniel Bourquin; Rudolf Brenneisen; Franz Vollenweider
Renal excretion profiles of psilocin following oral administration of psilocybin: a controlled study in man.
Journal of pharmaceutical and biomedical analysis 2002;30(2):331-9.
2002: Katja Ludewig; Mark A Geyer; Mario Etzensberger; Franz Vollenweider
Stability of the acoustic startle reflex, prepulse inhibition, and habituation in schizophrenia.
Schizophrenia research 2002;55(1-2):129-37.
2002: Katja Ludewig; Franz Vollenweider
Impaired sensorimotor gating in schizophrenia with deficit and with nondeficit syndrome.
Swiss medical weekly 2002;132(13-14):159-65.
2002: Franz Vollenweider; Matthias E Liechti; Alex Gamma; George Greer; Mark A Geyer
Acute psychological and neurophysiological effects of MDMA in humans.
Journal of psychoactive drugs 2002;34(2):171-84.
2002: Daniel Umbricht; Rupert Koller; Franz Vollenweider; Liselotte Schmid
Mismatch negativity predicts psychotic experiences induced by NMDA receptor antagonist in healthy volunteers.
Biological psychiatry 2002;51(5):400-6.
2002: Stephan Ludewig; Katja Ludewig; Mark A Geyer; Daniel Hell; Franz Vollenweider
Prepulse inhibition deficits in patients with panic disorder.
Depression and anxiety 2002;15(2):55-60.
2002: Roland D Schönbächler; Pascale M Gucker; Michele Arigoni; Stefan Kneifel; Franz Vollenweider; Alfred Buck; Cyrill Burger; Thomas Berthold; Matthias Brühlmeier; P August Schubiger; Simon M Ametamey
PET imaging of dopamine transporters in the human brain using [(11)C]-beta-CPPIT, a cocaine derivative lacking the 2 beta-ester function.
Nuclear medicine and biology 2002;29(1):19-27.
2001: Franz Vollenweider
Brain mechanisms of hallucinogens and entactogens.
Dialogues in clinical neuroscience 2001;3(4):265-79.
2001: Franz Vollenweider; Mark A Geyer
A systems model of altered consciousness: integrating natural and drug-induced psychoses.
Brain research bulletin 2001;56(5):495-507.
2001: E Frei; Alex Gamma; Roberto D Pascual-Marqui; Dietrich Lehmann; D Hell; Franz Vollenweider
Localization of MDMA-induced brain activity in healthy volunteers using low resolution brain electromagnetic tomography (LORETA).
Human brain mapping 2001;14(3):152-65.
2001: L Leumann; D Sterchi; Franz Vollenweider; Katja Ludewig; H Früh
A neural network approach to the acoustic startle reflex and prepulse inhibition.
Brain research bulletin 2001;56(2):101-10.
2001: Franz Vollenweider; R T Jones; Matthew Baggott
Caveat emptor: editors beware.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;24(4):461-3.
2001: Matthias E Liechti; Alex Gamma; Franz Vollenweider
Gender differences in the subjective effects of MDMA.
Psychopharmacology 2001;154(2):161-8.
2001: Matthias E Liechti; Mark A Geyer; Daniel Hell; Franz Vollenweider
Effects of MDMA (ecstasy) on prepulse inhibition and habituation of startle in humans after pretreatment with citalopram, haloperidol, or ketanserin.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2001;24(3):240-52.
2001: Alex Gamma; Alfred Buck; Thomas Berthold; Franz Vollenweider
No difference in brain activation during cognitive performance between ecstasy (3,4-methylenedioxymethamphetamine) users and control subjects: a [H2(15)O]-positron emission tomography study.
Journal of clinical psychopharmacology 2001;21(1):66-71.
2000: Daniel Umbricht; Liselotte Schmid; Rupert Koller; Franz Vollenweider; Daniel Hell; D C Javitt
Ketamine-induced deficits in auditory and visual context-dependent processing in healthy volunteers: implications for models of cognitive deficits in schizophrenia.
Archives of general psychiatry 2000;57(12):1139-47.
2000: Matthias E Liechti; M R Saur; Alex Gamma; Daniel Hell; Franz Vollenweider
Psychological and physiological effects of MDMA ("Ecstasy") after pretreatment with the 5-HT(2) antagonist ketanserin in healthy humans.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(4):396-404.
2000: Alex Gamma; Alfred Buck; Thomas Berthold; Matthias E Liechti; Franz Vollenweider; D Hell
3,4-Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H(2)(15)O]-PET in healthy humans.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(4):388-95.
2000: MF Vollenweider-Scherpenhuyzen; Franz Vollenweider
[Emergencies due to drug abuse].
Der Internist 2000;41(9):886-98.
2000: Matthias E Liechti; Franz Vollenweider
Acute psychological and physiological effects of MDMA ("Ecstasy") after haloperidol pretreatment in healthy humans.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2000;10(4):289-95.
2000: Matthias E Liechti; C Baumann; Alex Gamma; Franz Vollenweider
Acute psychological effects of 3,4-methylenedioxymethamphetamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;22(5):513-21.
2000: Alfred Buck; P M Gucker; R D Schönbächler; Michele Arigoni; Stefan Kneifel; Franz Vollenweider; Simon M Ametamey; Cyrill Burger
Evaluation of serotonergic transporters using PET and [11C](+)McN-5652: assessment of methods.
Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 2000;20(2):253-62.
2000: Alex Gamma; E Frei; Dietrich Lehmann; Roberto D Pascual-Marqui; D Hell; Franz Vollenweider
Mood state and brain electric activity in ecstasy users.
Neuroreport 2000;11(1):157-62.
2000: Matthias E Liechti; Franz Vollenweider
The serotonin uptake inhibitor citalopram reduces acute cardiovascular and vegetative effects of 3,4-methylenedioxymethamphetamine ('Ecstasy') in healthy volunteers.
Journal of psychopharmacology (Oxford, England) 2000;14(3):269-74.
2000: Franz Vollenweider; P Vontobel; I Oye; Daniel Hell; Klaus L Leenders
Effects of (S)-ketamine on striatal dopamine: a [11C]raclopride PET study of a model psychosis in humans.
Journal of psychiatric research 2000;34(1):35-43.
1999: Franz Vollenweider; Alex Gamma; Matthias E Liechti; T Huber
Is a single dose of MDMA harmless?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;21(4):598-600.
1999: Franz Vollenweider; P Vontobel; Daniel Hell; Klaus L Leenders
5-HT modulation of dopamine release in basal ganglia in psilocybin-induced psychosis in man--a PET study with [11C]raclopride.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1999;20(5):424-33.
1999: Franz Vollenweider; S Remensberger; Daniel Hell; Mark A Geyer
Opposite effects of 3,4-methylenedioxymethamphetamine (MDMA) on sensorimotor gating in rats versus healthy humans.
Psychopharmacology 1999;143(4):365-72.
1998: Franz Vollenweider; MF Vollenweider-Scherpenhuyzen; A Bäbler; H Vogel; Daniel Hell
Psilocybin induces schizophrenia-like psychosis in humans via a serotonin-2 agonist action.
Neuroreport 1998;9(17):3897-902.
1998: MF Vollenweider-Scherpenhuyzen; Franz Vollenweider
[The drug emergency].
Der Anaesthesist 1998;47(11):946-55.
1998: Franz Vollenweider; Alex Gamma; Matthias E Liechti; T Huber
Psychological and cardiovascular effects and short-term sequelae of MDMA ("ecstasy") in MDMA-naïve healthy volunteers.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1998;19(4):241-51.
1998: Franz Vollenweider; R P Maguire; Klaus L Leenders; K Mathys; J Angst
Effects of high amphetamine dose on mood and cerebral glucose metabolism in normal volunteers using positron emission tomography (PET).
Psychiatry research 1998;83(3):149-62.
1998: Franz Vollenweider
Advances and pathophysiological models of hallucinogenic drug actions in humans: a preamble to schizophrenia research.
Pharmacopsychiatry 1998;31 Suppl 2():92-103.
1997: Felix Hasler; Daniel Bourquin; Rudolf Brenneisen; T Bär; Franz Vollenweider
Determination of psilocin and 4-hydroxyindole-3-acetic acid in plasma by HPLC-ECD and pharmacokinetic profiles of oral and intravenous psilocybin in man.
Pharmaceutica acta Helvetiae 1997;72(3):175-84.
1997: Franz Vollenweider; Klaus L Leenders; Christian Scharfetter; P Maguire; O Stadelmann; Jules Angst
Positron emission tomography and fluorodeoxyglucose studies of metabolic hyperfrontality and psychopathology in the psilocybin model of psychosis.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1997;16(5):357-72.
1997: Franz Vollenweider; Klaus L Leenders; I Oye; Daniel Hell; Jules Angst
Differential psychopathology and patterns of cerebral glucose utilisation produced by (S)- and (R)-ketamine in healthy volunteers using positron emission tomography (PET).
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1997;7(1):25-38.
1997: Franz Vollenweider; Klaus L Leenders; Christian Scharfetter; Angelo Antonini; P Maguire; J Missimer; Jules Angst
Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1997;7(1):9-24.
1995: NP Feng; Franz Vollenweider; E I Minder; Katharina M Rentsch; T Grampp; D J Vonderschmitt
Development of a gas chromatography-mass spectrometry method for determination of ketamine in plasma and its application to human samples.
Therapeutic drug monitoring 1995;17(1):95-100.
1990: Franz Vollenweider; M Cuénod; Kim Q Do
Effect of climbing fiber deprivation on release of endogenous aspartate, glutamate, and homocysteate in slices of rat cerebellar hemispheres and vermis.
Journal of neurochemistry 1990;54(5):1533-40.